Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Edit functionality is currently unavailable.

John J. Worthington III, M.D.

Co-Author

This page shows the publications co-authored by John Worthington and Maurizio Fava.
Connection Strength

1.770
  1. Fava M, Farabaugh AH, Sickinger AH, Wright E, Alpert JE, Sonawalla S, Nierenberg AA, Worthington JJ. Personality disorders and depression. Psychol Med. 2002 Aug; 32(6):1049-57.
    View in: PubMed
    Score: 0.283
  2. Fava M, Rankin MA, Alpert JE, Nierenberg AA, Worthington JJ. An open trial of oral sildenafilin antidepressant-induced sexual dysfunction. Psychother Psychosom. 1998; 67(6):328-31.
    View in: PubMed
    Score: 0.206
  3. Papakostas GI, Worthington JJ, Iosifescu DV, Kinrys G, Burns AM, Fisher LB, Homberger CH, Mischoulon D, Fava M. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety. 2006; 23(3):178-81.
    View in: PubMed
    Score: 0.090
  4. Alpert JE, Papakostas G, Mischoulon D, Worthington JJ, Petersen T, Mahal Y, Burns A, Bottiglieri T, Nierenberg AA, Fava M. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol. 2004 Dec; 24(6):661-4.
    View in: PubMed
    Score: 0.083
  5. Nierenberg AA, Papakostas GI, Petersen T, Montoya HD, Worthington JJ, Tedlow J, Alpert JE, Fava M. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol. 2003 Feb; 23(1):92-5.
    View in: PubMed
    Score: 0.073
  6. Nierenberg AA, Papakostas GI, Petersen T, Kelly KE, Iacoviello BM, Worthington JJ, Tedlow J, Alpert JE, Fava M. Nortriptyline for treatment-resistant depression. J Clin Psychiatry. 2003 Jan; 64(1):35-9.
    View in: PubMed
    Score: 0.073
  7. Fava M, Alpert J, Nierenberg A, Lagomasino I, Sonawalla S, Tedlow J, Worthington J, Baer L, Rosenbaum JF. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol. 2002 Aug; 22(4):379-87.
    View in: PubMed
    Score: 0.071
  8. Nierenberg AA, Phillips KA, Petersen TJ, Kelly KE, Alpert JE, Worthington JJ, Tedlow JR, Rosenbaum JF, Fava M. Body dysmorphic disorder in outpatients with major depression. J Affect Disord. 2002 May; 69(1-3):141-8.
    View in: PubMed
    Score: 0.069
  9. Iosifescu DV, Howarth S, Alpert JE, Nierenberg AA, Worthington JJ, Fava M. T3 blood levels and treatment outcome in depression. Int J Psychiatry Med. 2001; 31(4):367-73.
    View in: PubMed
    Score: 0.063
  10. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, Worthington JJ, Rosenbaum JF, Fava M. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry. 2000 Sep; 157(9):1423-8.
    View in: PubMed
    Score: 0.062
  11. Baker A, Simon N, Keshaviah A, Farabaugh A, Deckersbach T, Worthington JJ, Hoge E, Fava M, Pollack MP. Anxiety Symptoms Questionnaire (ASQ): development and validation. Gen Psychiatr. 2019; 32(6):e100144.
    View in: PubMed
    Score: 0.059
  12. Nierenberg AA, Keefe BR, Leslie VC, Alpert JE, Pava JA, Worthington JJ, Rosenbaum JF, Fava M. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999 Apr; 60(4):221-5.
    View in: PubMed
    Score: 0.056
  13. Vance MC, Bui E, Hoeppner SS, Kovachy B, Prescott J, Mischoulon D, Walton ZE, Dong M, Nadal MF, Worthington JJ, Hoge EA, Cassano P, Orr EH, Fava M, de Vivo I, Wong KK, Simon NM. Prospective association between major depressive disorder and leukocyte telomere length over two years. Psychoneuroendocrinology. 2018 04; 90:157-164.
    View in: PubMed
    Score: 0.052
  14. Alpert JE, Uebelacker LA, McLean NE, Nierenberg AA, Pava JA, Worthington JJ, Tedlow JR, Rosenbaum JF, Fava M. Social phobia, avoidant personality disorder and atypical depression: co-occurrence and clinical implications. Psychol Med. 1997 May; 27(3):627-33.
    View in: PubMed
    Score: 0.049
  15. Spillmann M, Borus JS, Davidson KG, Worthington JJ, Tedlow JR, Fava M. Sociodemographic predictors of response to antidepressant treatment. Int J Psychiatry Med. 1997; 27(2):129-36.
    View in: PubMed
    Score: 0.048
  16. Worthington J, Fava M, Agustin C, Alpert J, Nierenberg AA, Pava JA, Rosenbaum JF. Consumption of alcohol, nicotine, and caffeine among depressed outpatients. Relationship with response to treatment. Psychosomatics. 1996 Nov-Dec; 37(6):518-22.
    View in: PubMed
    Score: 0.047
  17. Fava M, Davidson K, Alpert JE, Nierenberg AA, Worthington J, O'Sullivan R, Rosenbaum JF. Hostility changes following antidepressant treatment: relationship to stress and negative thinking. J Psychiatr Res. 1996 Nov-Dec; 30(6):459-67.
    View in: PubMed
    Score: 0.047
  18. Cassano P, Bui E, Rogers AH, Walton ZE, Ross R, Zeng M, Nadal-Vicens M, Mischoulon D, Baker AW, Keshaviah A, Worthington J, Hoge EA, Alpert J, Fava M, Wong KK, Simon NM. Inflammatory cytokines in major depressive disorder: A case-control study. Aust N Z J Psychiatry. 2017 Jan; 51(1):23-31.
    View in: PubMed
    Score: 0.047
  19. Alpert JE, Maddocks A, Nierenberg AA, O'Sullivan R, Pava JA, Worthington JJ, Biederman J, Rosenbaum JF, Fava M. Attention deficit hyperactivity disorder in childhood among adults with major depression. Psychiatry Res. 1996 Jun 01; 62(3):213-9.
    View in: PubMed
    Score: 0.046
  20. Fava M, Alpert J, Nierenberg AA, Ghaemi N, O'Sullivan R, Tedlow J, Worthington J, Rosenbaum JF. Fluoxetine treatment of anger attacks: a replication study. Ann Clin Psychiatry. 1996 Mar; 8(1):7-10.
    View in: PubMed
    Score: 0.045
  21. Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry. 1995 Oct; 152(10):1500-3.
    View in: PubMed
    Score: 0.044
  22. Simon NM, Walton ZE, Bui E, Prescott J, Hoge E, Keshaviah A, Schwarz N, Dryman T, Ojserkis RA, Kovachy B, Mischoulon D, Worthington J, De Vivo I, Fava M, Wong KK. Telomere length and telomerase in a well-characterized sample of individuals with major depressive disorder compared to controls. Psychoneuroendocrinology. 2015 Aug; 58:9-22.
    View in: PubMed
    Score: 0.043
  23. Worthington J, Fava M, Davidson K, Alpert J, Nierenberg AA, Rosenbaum JF. Patterns of improvement in depressive symptoms with fluoxetine treatment. Psychopharmacol Bull. 1995; 31(2):223-6.
    View in: PubMed
    Score: 0.042
  24. Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, Fava M, Nierenberg AA. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry. 2005 Oct; 66(10):1326-30.
    View in: PubMed
    Score: 0.022
  25. Papakostas GI, Petersen T, Worthington JJ, Roffi PA, Alpert JE, Fava M, Nierenberg AA. A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed. Int Clin Psychopharmacol. 2003 Sep; 18(5):293-6.
    View in: PubMed
    Score: 0.019
  26. Mischoulon D, Burger JK, Spillmann MK, Worthington JJ, Fava M, Alpert JE. Anemia and macrocytosis in the prediction of serum folate and vitamin B12 status, and treatment outcome in major depression. J Psychosom Res. 2000 Sep; 49(3):183-7.
    View in: PubMed
    Score: 0.015
  27. Alpert JE, Fava M, Uebelacker LA, Nierenberg AA, Pava JA, Worthington JJ, Rosenbaum JF. Patterns of axis I comorbidity in early-onset versus late-onset major depressive disorder. Biol Psychiatry. 1999 Jul 15; 46(2):202-11.
    View in: PubMed
    Score: 0.014
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.